Clinical Significance of Thrombin Blockade with Low Doses (2.5 mg) of Rivaroxaban in Ischemic Heart Disease Patients

Por A. B. Sumarokov, L. I. Buryachkovskaya, Y. V. Docenko, M. S. Kurochkin, N. V. Lomakin
Publicado em 2020-03-01